Drug treatment strategies for osteoporosis in stroke patients

References

• The GBD 2016 Lifetime Risk of Stroke Collaborators. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. N Engl J Med. 2018;379(25):2429–2437.
   PubMed Web of Science ®Google Scholar
• Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383(9913):245–255.
   PubMed Web of Science ®Google Scholar
• Kanis J, Oden A, Johnell O. Acute and long-term increase in fracture risk after hospitalization for stroke. Stroke. 2001;32(3):702–706.
   PubMed Web of Science ®Google Scholar
• Marsden J, Gibson LM, Lightbody CE, et al. Can early onset bone loss be effectively managed in post-stroke patients? An integrative review of the evidence. Age Ageing. 2008;37(2):142–150.
   PubMed Web of Science ®Google Scholar
• Huo K. Impact and risk factors of post-stroke bone fracture. World J Exp Med. 2016;6(1):1.
   PubMedGoogle Scholar
• Kapral MK, Fang J, Alibhai SMH, et al., Risk of fractures after stroke: results from the Ontario Stroke Registry. Neurology. 2017;88(1):57–64.
   PubMed Web of Science ®Google Scholar
• Forster A, Young J. Incidence and consequences of falls due to stroke: a systematic inquiry. BMJ. 1995;311(6997):83–86.
   PubMed Web of Science ®Google Scholar
• Eng JJ. Balance, falls, and bone health: role of exercise in reducing fracture risk after stroke. J Rehabil Res Dev. 2008;45(2):297–314.
   PubMedGoogle Scholar
• Fontalis A, Kenanidis E, Kotronias RA, et al., Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss. Expert Opin Pharmacother. 2019;20(9):1123–1134.
   PubMed Web of Science ®Google Scholar
• Borschmann K, Pang MYC, Bernhardt J, et al. Stepping towards prevention of bone loss after stroke: a systematic review of the skeletal effects of physical activity after stroke. Int J Stroke. 2012;7(4):330–335.
   PubMed Web of Science ®Google Scholar
• Carda S, Cisari C, Invernizzi M, et al. Osteoporosis after stroke: A review of the causes and potential treatments. Cerebrovasc Dis. 2009;28(2):191–200.
   PubMed Web of Science ®Google Scholar
• Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016;47(6):e98–e169.
   PubMed Web of Science ®Google Scholar
• Papaioannou A, Morin S, Cheung AM, et al. clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Can Med Assoc J. 2010;182(17):1864–1873.
   PubMed Web of Science ®Google Scholar
• Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381.
   PubMed Web of Science ®Google Scholar
• Dennis MS, Lo KM, McDowall M, et al. Fractures after stroke: frequency, types, and associations. Stroke. 2002;33(3):728–734.
   PubMed Web of Science ®Google Scholar
• Brown DL, Morgenstern LB, Majersik JJ, et al. Risk of fractures after stroke. Cerebrovasc Dis. 2008;25(1–2):95–99.
   PubMed Web of Science ®Google Scholar
• Whitson HE, Pieper CF, Sanders L, et al. Adding injury to insult: fracture risk after stroke in veterans. J Am Geriatr Soc. 2006;54(7):1082–1088.
   PubMed Web of Science ®Google Scholar
• Kerse N, Parag V, Feigin VL, et al. Falls after stroke: results from the Auckland Regional Community Stroke (ARCOS) Study, 2002 to 2003. Stroke. 2008;39(6):1890–1893.
   PubMed Web of Science ®Google Scholar
• Cauley JA, Chalhoub D, Kassem AM, et al. Geographic and ethnic disparities in osteoporotic fractures. Nat Rev Endocrinol. 2014;10(6):338–351.
   PubMed Web of Science ®Google Scholar
• Lee KB, Lee J-G, Kim BJ, et al. The epidemiology of fracture in patients with acute ischemic stroke in Korea. J Korean Med Sci. 2019;34(22):e164.
   PubMed Web of Science ®Google Scholar
• Jørgensen L, Jacobsen BK. Functional status of the paretic arm affects the loss of bone mineral in the proximal humerus after stroke: A 1-year prospective study. Calcif Tissue Int. 2001;68(1):11–15.
   PubMed Web of Science ®Google Scholar
• Jørgensen L, Jacobsen BK. Changes in muscle mass, fat mass, and bone mineral content in the legs after stroke: a 1 year prospective study. Bone. 2001;28(6):655–659.
   PubMed Web of Science ®Google Scholar
• Jørgensen L, Crabtree NJ, Reeve J, et al. Ambulatory level and asymmetrical weight bearing after stroke affects bone loss in the upper and lower part of the femoral neck differently: bone adaptation after decreased mechanical loading. Bone. 2000;27(5):701–707.
   PubMed Web of Science ®Google Scholar
• Ashe MC, Fehling P, Eng JJ, et al. Bone geometric response to chronic disuse following stroke: a pQCT study. J Musculoskelet Neuronal Interact. 2006;6(3):226–233.
   PubMedGoogle Scholar
• Pang MYC, Ashe MC, Eng JJ. Muscle weakness, spasticity and disuse contribute to demineralization and geometric changes in the radius following chronic stroke. Osteoporos Int. 2007;18(9):1243–1252.
   PubMed Web of Science ®Google Scholar
• Pang MYC, Eng JJ, McKay HA, et al. Reduced hip bone mineral density is related to physical fitness and leg lean mass in ambulatory individuals with chronic stroke. Osteoporos Int. 2005;16(12):1769–1779.
   PubMed Web of Science ®Google Scholar
• Lam FMH, Bui M, Yang FZH, et al. Chronic effects of stroke on hip bone density and tibial morphology: a longitudinal study. Osteoporos Int. 2016;27(2):591–603.
   PubMed Web of Science ®Google Scholar
• Belgen B, Beninato M, Sullivan PE, et al. The association of balance capacity and falls self-efficacy with history of falling in community-dwelling people with chronic stroke. Arch Phys Med Rehabil. 2006;87(4):554–561.
   PubMed Web of Science ®Google Scholar
• Cappellesso R, Nicole L, Guido A, et al. Spaceflight osteoporosis: current state and future perspective. Endocr Regul. 2015;49(4):231–239.
   PubMedGoogle Scholar
• Minaire P. Immobilization osteoporosis: a review. Clin Rheumatol. 1989;8(S2):95–103.
   PubMedGoogle Scholar
• Worthen LC, Kim CM, Kautz SA, et al. Key characteristics of walking correlate with bone density in individuals with chronic stroke. J Rehabil Res Dev. 2005;42(6):761.
   PubMed Web of Science ®Google Scholar
• Berghout BP, Fani L, Heshmatollah A, et al. Vitamin D status and risk of stroke: the Rotterdam study. Stroke. 2019;50(9):2293–2298.
   PubMed Web of Science ®Google Scholar
• Poole KES, Reeve J, Warburton EA. Falls, fractures, and osteoporosis after stroke: time to think about protection? Stroke. 2002;33(5):1432–1436.
   PubMed Web of Science ®Google Scholar
• Poole KES, Loveridge N, Barker PJ, et al. Reduced vitamin D in acute stroke. Stroke. 2006;37(1):243–245.
   PubMed Web of Science ®Google Scholar
• Fujimatsu Y. Role of the parathyroid gland on bone mass and metabolism in immobilized stroke patients. Kurume Med J. 1998;45(3):265–270.
   PubMedGoogle Scholar
• Ahmed S, Bogiatzi C, Hackam DG, et al. Vitamin B12 deficiency and hyperhomocysteinaemia in outpatients with stroke or transient ischaemic attack: a cohort study at an academic medical centre. BMJ Open. 2019;9(1):e026564.
   PubMed Web of Science ®Google Scholar
• van Meurs JBJ, Dhonukshe-Rutten RAM, Pluijm SMF, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med. 2004;350(20):2033–2041.
   PubMed Web of Science ®Google Scholar
• Gage BF, Birman-Deych E, Radford MJ, et al. Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med. 2006;166(2):241.
   PubMed Web of Science ®Google Scholar
• Kapoor E, Austin PC, Alibhai SMH, et al., Screening and treatment for osteoporosis after stroke: results from the Ontario Stroke Registry. Stroke. 2019;50(6):1564–1566.
   PubMed Web of Science ®Google Scholar
• Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595–1622.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden A, et al. FRAXTM and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385–397.
   PubMed Web of Science ®Google Scholar
• Viscoli CM, Kent DM, Conwit R, et al. Scoring system to optimize pioglitazone therapy after stroke based on fracture risk. Stroke. 2018 Dec 10. STROKEAHA118022745. Epub ahead of print. DOI: 10.1161/STROKEAHA.118.022745.
   PubMed Web of Science ®Google Scholar
• Smith EE, Fang J, Alibhai SM, et al. Derivation and external validation of a scoring system for predicting fracture risk after ischemic stroke in a Canadian cohort. JAMA Neurol. 2019 May 13;76(8):925. Epub ahead of print.
   Web of Science ®Google Scholar
• Body -J-J, Bergmann P, Boonen S, et al. Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporos Int. 2012;23(S1):1–23.
   PubMedGoogle Scholar
• Makariou S, Michel P, Tzoufi M, et al. Vitamin D and stroke: promise for prevention and better outcome. Curr Vasc Pharmacol. 2014;12(1):117–124.
   PubMed Web of Science ®Google Scholar
• Watts NB. Postmenopausal osteoporosis: A clinical review. J Womens Health. 2018;27(9):1093–1096.
   PubMed Web of Science ®Google Scholar
• Chen L-R, Ko N-Y, Chen K-H. Medical treatment for osteoporosis: from molecular to clinical opinions. Int J Mol Sci. 2019;20(9):E2213.
   PubMed Web of Science ®Google Scholar
• Kim DH, Rogers JR, Fulchino LA, et al. Bisphosphonates and risk of cardiovascular events: A meta-analysis. PLoS ONE. 2015;10(4):e0122646.
   PubMed Web of Science ®Google Scholar
• Reid IR, Horne AM, Mihov B, et al. Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women. J Bone Miner Res. 2020;35(1):20–27.
   PubMed Web of Science ®Google Scholar
• Ikai T, Uematsu M, Eun SS, et al. Prevention of secondary osteoporosis postmenopause in hemiplegia. Am J Phys Med Rehabil. 2001;80(3):169–174.
   PubMed Web of Science ®Google Scholar
• Watts NB, Chesnut CH, Genant HK, et al. History of etidronate. Bone. 2020 Jan 3:115222. Epub ahead of print. DOI: 10.1016/j.bone.2020.115222.
   PubMed Web of Science ®Google Scholar
• Peter R, Mishra V, Fraser WD. Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ. 2004;328(7435):335–336.
   PubMedGoogle Scholar
• Orwoll ES, Miller PD, Adachi JD, et al. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res. 2010;25(10):2239–2250.
   PubMed Web of Science ®Google Scholar
• Poole KES, Loveridge N, Rose CM, et al. A single infusion of zoledronate prevents bone loss after stroke. Stroke. 2007;38(5):1519–1525.
   PubMed Web of Science ®Google Scholar
• Poole KES, Vedi S, Debiram I, et al. Bone structure and remodelling in stroke patients: early effects of zoledronate. Bone. 2009;44(4):629–633.
   PubMed Web of Science ®Google Scholar
• Sugiyama T. Letter by Sugiyama regarding article, “Screening and treatment for osteoporosis after stroke: results from the Ontario Stroke Registry.” Stroke. 2019;50(10):e307.
   PubMed Web of Science ®Google Scholar
• Rosen CJ, Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med. 2003;348(15):1503–1504.
   PubMed Web of Science ®Google Scholar
• Cheung AM, Kapral MK. Response by Cheung and Kapral to letter regarding article, “Screening and treatment for osteoporosis after stroke: results from the Ontario Stroke Registry.” Stroke. 2019;50(10):e308.
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–1822.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med. 2007;356(18):1895–1896.
   PubMed Web of Science ®Google Scholar
• Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: A randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2015;30(5):934–944.
   PubMed Web of Science ®Google Scholar
• Reid IR, Horne AM, Mihov B, et al. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med. 2018;379(25):2407–2416.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765.
   PubMed Web of Science ®Google Scholar
• Komm BS, Morgenstern D, A Yamamoto L, et al. The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women. Expert Rev Clin Pharmacol. 2015;8(6):769–784.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Chen C, Zhang J, et al. Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis. Int J Clin Exp Pathol. 2014;7(5):2113–2122.
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health initiative randomized trials. JAMA. 2013;310(13):1353–1368.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Delmas PD, Stathopoulos V, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359(7):697–708.
   PubMed Web of Science ®Google Scholar
• Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial*. J Bone Miner Res. 2008;23(12):1923–1934.
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Grady D. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125–137.
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–1441.
   PubMed Web of Science ®Google Scholar
• Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391(10117):230–240.
   PubMed Web of Science ®Google Scholar
• Minisola S, Cipriani C, Grotta GD, et al. Update on the safety and efficacy of teriparatide in the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2019;11:1759720X19877994.
   PubMed Web of Science ®Google Scholar
• Gilsenan A, Harding A, Kellier-Steele N, et al. The forteo patient registry linkage to multiple state cancer registries: study design and results from the first 8 years. Osteoporos Int. 2018;29(10):2335–2343.
   PubMed Web of Science ®Google Scholar
• Leder BZ, O’Dea LS, Zanchetta JR, et al. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2015;100(2):697–706.
   PubMed Web of Science ®Google Scholar
• Merlotti D, Falchetti A, Chiodini I, et al. Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis. Expert Opin Pharmacother. 2019;20(7):805–811.
   PubMed Web of Science ®Google Scholar
• Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial. JAMA. 2016;316(7):722–733.
   PubMed Web of Science ®Google Scholar
• Drug trial snapshot: TYMLOS. Washington, DC: FDA, 2017. [updated 2019 Nov 14]. Available from: www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshot-tymlos
   Google Scholar
• Reginster JY, Bianic F, Campbell R, et al. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int. 2019;30(7):1465–1473.
   PubMed Web of Science ®Google Scholar
• McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412–420.
   PubMed Web of Science ®Google Scholar
• Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–1427.
   PubMed Web of Science ®Google Scholar
• Evenepoel P, D’Haese P, Brandenburg V. Romosozumab in postmenopausal women with osteopenia. N Engl J Med. 2014;370:1664.
   PubMed Web of Science ®Google Scholar
• Hsieh C-Y, Wu DP, Sung S-F. Trends in vascular risk factors, stroke performance measures, and outcomes in patients with first-ever ischemic stroke in Taiwan between 2000 and 2012. J Neurol Sci. 2017;378:80–84.
   PubMed Web of Science ®Google Scholar
• An T, Hao J, Sun S, et al. Efficacy of statins for osteoporosis: a systematic review and meta-analysis. Osteoporos Int. 2017;28(1):47–57.
   PubMed Web of Science ®Google Scholar
• Ozen G, Pedro S, Wolfe F, et al. Medications associated with fracture risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78(8):1041–1047.
   PubMed Web of Science ®Google Scholar
• Lin S-M, Wang J-H, Liang -C-C, et al. Statin use is associated with decreased osteoporosis and fracture risks in stroke patients. J Clin Endocrinol Metab. 2018;103(9):3439–3448.
   PubMed Web of Science ®Google Scholar
• Leutner M, Matzhold C, Bellach L, et al. Diagnosis of osteoporosis in statin-treated patients is dose-dependent. Ann Rheum Dis. 2019;78(12):1706–1711.
   PubMed Web of Science ®Google Scholar
• Oryan A, Kamali A, Moshiri A. Potential mechanisms and applications of statins on osteogenesis: current modalities, conflicts and future directions. J Control Release. 2015;215:12–24.
   PubMed Web of Science ®Google Scholar
• Ruan F, Zheng Q, Wang J. Mechanisms of bone anabolism regulated by statins. Biosci Rep. 2012;32(6):511–519.
   PubMed Web of Science ®Google Scholar
• Middler S, Pak CYC, Murad F, et al. Thiazide diuretics and calcium metabolism. Metabolism. 1973;22(2):139–146.
   PubMed Web of Science ®Google Scholar
• Zerwekh JE, Pak CY. Selective effects of thiazide therapy on serum l alpha,25- dihydroxyvitamin D and intestinal calcium absorption in renal and absorptive hypercalciurias. Metabolism. 1980;29(1):13–17.
   PubMed Web of Science ®Google Scholar
• Dvorak MM, De Joussineau C, Carter DH, et al. Thiazide diuretics directly induce osteoblast differentiation and mineralized nodule formation by interacting with a sodium chloride co-transporter in bone. J Am Soc Nephrol. 2007;18(9):2509–2516.
   PubMed Web of Science ®Google Scholar
• Miltiadous G, Mikhailidis DP, Elisaf M. Acid-base and electrolyte abnormalities observed in patients receiving cardiovascular drugs. J Cardiovasc Pharmacol Ther. 2003;8(4):267–276.
   PubMedGoogle Scholar
• Aung K, Htay T. Thiazide diuretics and the risk of hip fracture. Cochrane Database Syst Rev. 2011;(10):CD005185. DOI: 10.1002/14651858.CD005185.pub2.
   PubMed Web of Science ®Google Scholar
• Lin S-M, Yang S-H, Cheng H-Y, et al. Thiazide diuretics and the risk of hip fracture after stroke: a population-based propensity-matched cohort study using Taiwan’s National Health Insurance Research Database. BMJ Open. 2017;7(9):e016992.
   PubMed Web of Science ®Google Scholar
• Signorelli SS, Scuto S, Marino E, et al. Anticoagulants and osteoporosis. Int J Mol Sci. 2019;20(21):E5275.
   PubMed Web of Science ®Google Scholar
• Morishima Y, Kamisato C, Honda Y, et al. The effects of warfarin and edoxaban, an oral direct factor Xa inhibitor, on gammacarboxylated (Gla-osteocalcin) and undercarboxylated osteocalcin (uc-osteocalcin) in rats. Thromb Res. 2013;131(1):59–63.
   PubMed Web of Science ®Google Scholar
• Tufano A, Coppola A, Contaldi P, et al. Oral anticoagulant drugs and the risk of osteoporosis: new anticoagulants better than old? Semin Thromb Hemost. 2015;41(4):382–388.
   PubMed Web of Science ®Google Scholar
• Fiordellisi W, White K, Schweizer M. A systematic review and meta-analysis of the association between vitamin K antagonist use and fracture. J Gen Intern Med. 2019;34(2):304–311.
   PubMed Web of Science ®Google Scholar
• Lau WCY, Man KKC, Wong ICK. Vitamin K antagonist use and fracture. J Gen Intern Med. 2020;35(1):396–397.
   PubMed Web of Science ®Google Scholar
• Binding C, Bjerring Olesen J, Abrahamsen B, et al. Osteoporotic fractures in patients with atrial fibrillation treated with conventional versus direct anticoagulants. J Am Coll Cardiol. 2019;74(17):2150–2158.
   PubMed Web of Science ®Google Scholar
• Lutsey PL, Norby FL, Ensrud KE, et al. Association of anticoagulant therapy with risk of fracture among patients with atrial fibrillation. JAMA Intern Med. 2019 Nov 25 Epub ahead of print. DOI:10.1001/jamainternmed.2019.5679.
   Web of Science ®Google Scholar
• Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344–e418.
   PubMed Web of Science ®Google Scholar
• Muir JM, Hirsh J, Weitz JI, et al. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood. 1997;89(9):3236–3242.
   PubMed Web of Science ®Google Scholar
• Irie A, Takami M, Kubo H, et al. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone. 2007;41(2):165–174.
   PubMed Web of Science ®Google Scholar
• Dahlman TC, Sjöberg HE, Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol. 1994;170(5):1315–1320.
   PubMed Web of Science ®Google Scholar
• Monreal M, Lafoz E, Olive A, et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost. 1994;71(1):7–11.
   PubMed Web of Science ®Google Scholar
• Lin S-M, Yang S-H, Liang -C-C, et al. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study. Osteoporos Int. 2018;29(1):153–162.
   PubMed Web of Science ®Google Scholar
• O’Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: A randomized crossover trial. Am J Med. 2005;118(7):778–781.
   PubMed Web of Science ®Google Scholar
• Costa-Rodrigues J, Reis S, Teixeira S, et al. Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity. Febs J. 2013;280(20):5052–5064.
   PubMed Web of Science ®Google Scholar
• Hansen KE, Nieves JW, Nudurupati S, et al. Dexlansoprazole and esomeprazole do not affect bone homeostasis in healthy postmenopausal women. Gastroenterology. 2019;156(4):926–934.e6.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157(3):682–691.e2.
   PubMed Web of Science ®Google Scholar
• Viscoli CM, Inzucchi SE, Young LH, et al. Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial. J Clin Endocrinol Metab. 2016;102:914–922.
   Web of Science ®Google Scholar
• Nicholas JM, Ridsdale L, Richardson MP, et al. Fracture risk with use of liver enzyme inducing antiepileptic drugs in people with active epilepsy: cohort study using the general practice research database. Seizure. 2013;22(1):37–42.
   PubMed Web of Science ®Google Scholar
• Warden SJ, Fuchs RK. Do selective serotonin reuptake inhibitors (SSRIs) cause fractures? Curr Osteoporos Rep. 2016;14(5):211–218.
   PubMed Web of Science ®Google Scholar